pamiparib

oral PARP 1/2 inhibitor

Also Known As:

(10aR)-2-Fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta(1,2,3,4-def)cyclopenta(a)fluoren-4(7H)-one; 5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)-; BGB-290

Networked: 18 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Fluorenes: 7
        pamiparib: 18
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Fluorenes: 7
    - pamiparib: 18

Experts

1.	Mu, Song: 4 articles (01/2022 - 01/2021)
2.	Skrzypczyk-Ostaszewicz, Anna: 2 articles (06/2022 - 01/2021)
3.	Li, Li: 2 articles (01/2022 - 01/2021)
4.	Li, Miao: 2 articles (01/2022 - 01/2021)
5.	Mu, Xiyan: 2 articles (01/2022 - 01/2021)
6.	Andreu-Vieyra, Claudia: 2 articles (01/2021 - 01/2021)
7.	Sahasranaman, Srikumar: 2 articles (01/2021 - 01/2021)
8.	Su, Dan: 2 articles (01/2021 - 01/2020)
9.	Tang, Zhiyu: 2 articles (01/2021 - 01/2020)
10.	Cheng, Ying: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Importantly, pamiparib attenuated tumor growth; while co-administration of pamiparib with PD-L1 blockers significantly improved the therapeutic efficacy in vivo compared with monotherapy. " 06/01/2022 - "On April 30, 2021, pamiparib obtained its first registration worldwide--it was approved in China for the treatment of women with recurrent ovarian, fallopian tube or primary peritoneal cancer with confirmed germline BRCA mutation." 06/01/2022 - "Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer." 01/01/2020 - "In SCLC-derived, TMZ-resistant H209 intracranial xenograft model, combination of pamiparib with TMZ overcomes its resistance and shows significant tumor inhibitory effects and prolonged life span. " 07/01/2021 - "Based on the results from the pivotal phase II portion of a phase I/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy. "
2.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2022 - "Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study." 01/01/2021 - "Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer." 01/05/2024 - "In this study, we established and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) based method to simultaneously quantify the four frequently prescripted PARP inhibitors, namely niraparib, olaparib，fluzoparib, and pamiparib, in ovarian cancer. " 11/12/2022 - "To investigate if such intense schedules are necessary, we determined the durability of PARP inhibition up to 72 h after a 1 h pulse of 1 µM of five of the approved PARPi, rucaparib, olaparib, niraparib, talazoparib and pamiparib, in IGROV-1 and ES-2 (human ovarian cancer) cells. "
3.	Breast Neoplasms (Breast Cancer) 02/01/2023 - "Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study." 02/01/2023 - "Pamiparib showed encouraging efficacy and an acceptable safety profile in patients with locally advanced and metastatic HER2- breast cancer with gBRCA1/2 m. " 01/01/2020 - "Pamiparib has good bioavailability and is 16-fold more potent than olaparib in an efficacy study using BRCA1 mutated MDA-MB-436 breast cancer xenograft model. " 02/01/2023 - "To evaluate the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2-) breast cancer, with deleterious or suspected deleterious germline BRCA1/2 mutations (gBRCA1/2 m). " 02/01/2023 - "In this open-label, phase II, multicenter study in China (NCT03575065), patients with triple-negative breast cancer (TNBC cohort) or hormone receptor-positive (HR+)/HER2- breast cancer (HR+/HER2- cohort) and ≤ 2 prior lines of chemotherapy received pamiparib 60 mg orally twice daily in 28-day, continuous cycles. "
4.	Stomach Neoplasms (Stomach Cancer) 01/01/2023 - "The PARALLEL-303 study (NCT03427814) investigated the efficacy and safety of pamiparib 60 mg orally (PO) twice daily (BID) versus placebo PO BID as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy. " 01/01/2023 - "Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results."
5.	Ovarian Epithelial Carcinoma 01/01/2022 - "Phase I results of this phase I/II study showed that pamiparib 60 mg twice a day had antitumor activity and an acceptable safety profile in Chinese patients with advanced cancer, including epithelial ovarian cancer. "

Related Drugs and Biologics

1.	Poly(ADP-ribose) Polymerase Inhibitors
2.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
3.	niraparib
4.	olaparib
5.	Platinum
6.	Cytochrome P-450 CYP3A Inhibitors
7.	Cytochrome P-450 CYP3A
8.	Itraconazole (Sporanox)
9.	Rifampin (Rifampicin)
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Oral Administration